Research programme: small molecule therapeutics - Chipscreen Biosciences

Drug Profile

Research programme: small molecule therapeutics - Chipscreen Biosciences

Alternative Names: CS 3158; CS 410; CS 510; CS00028; CS0220; CS0230; CS0240; CS0600; HDAC inhibitors - Chipscreen; Histone deacetylase inhibitors - Chipscreen Biosciences; Kinase inhibitors - Chipscreen Bioscience; VEGFR inhibitors - Chipscreen Biosciences

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chipscreen Biosciences
  • Class Small molecules
  • Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; Histone deacetylase inhibitors; Janus kinase 3 inhibitors; MAP kinase kinase kinase 5 inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Rheumatoid arthritis
  • No development reported Autoimmune disorders; Neurodegenerative disorders; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in China
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in China
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top